Background: The development of antibiotic resistance by bacteria is of global concern. Inappropriate prescribing has the potential to exacerbate this issue. We aimed to examine the patterns of prescribing of antimicrobial medicines by dental practitioners in Australia from 2001 to 2012. Methods: Data were collected from Medicare Australia on prescriptions from dental practitioners dispensed to concessional beneficiaries between 2001 and 2012. We examined patterns of use over time.
INTRODUCTION
Australian dentists prescribe antibacterial and antifungal medicines to treat oral and dental infections. 1 While antimicrobials are an important adjunct to the management of some dental conditions, it is critical that their use is judicious. Increasing antibiotic consumption at the population level is associated with the development of antibiotic resistance 2 and this issue is of global concern.
3 Although the contribution of dental prescribing of antimicrobials to the emergence of resistance is unknown, indiscriminate prescription of antibiotics has been identified as a major factor in its development. 3 Unnecessary prescribing of antibiotics also exposes patients to the risk of adverse reactions and increases costs associated with dental care.
Indications for dental prescribing of antimicrobials are limited because most dental infections are effectively treated with direct operative intervention, and antimicrobials are used only occasionally and as an adjunct. 4 However, when required, appropriate prescribing of a well-chosen antimicrobial can prevent potentially life-threatening sequelae of dental infections. In addition, certain patients (those with a narrow range of cardiac conditions) who are undergoing some invasive dental procedures require antibiotic prophylaxis to prevent endocarditis. 1 The guidelines for dental prescribing can be found in the Australian Therapeutic Guidelines (Oral and Dental; ATG). 1 There is evidence to suggest that dental practitioners may not adhere to clinical guidelines and tend to overprescribe antibiotics. [5] [6] [7] [8] [9] Antibacterial medicines are the most commonly prescribed antimicrobials in dentistry. 4 A narrowspectrum penicillin such as phenoxymethylpenicillin is the drug of choice for acute odontogenic infections as recommended by the ATG. 1 While narrow in spectrum, it is effective against 85% of oral bacteria (mainly Gram-positive organisms). The ATG suggest amoxicillin as a second preference for this indication. Although it has a somewhat broader spectrum (effective against 91% of oral bacteria), its use in the treatment of dental infections is discouraged in order to reduce the development of resistance in Streptococcus pneumoniae. Amoxicillin is also more likely to cause adverse effects such as gastrointestinal problems and rashes. 1 Where penicillin is not tolerated, clindamycin or lincomycin is recommended. Penicillins are inactivated by the b-lactamase enzyme produced by some organisms. 10 The addition of clavulanate inhibits this enzyme and increases the spectrum of activity of the antibiotic. Amoxicillin plus clavulanate combinations, however, should not be the first line of treatment for odontogenic infections, where a narrow spectrum antibiotic is likely to be as effective and to present less risk of adverse reactions. 11 Metronidazole is effective against infections caused by anaerobic bacteria and is the recommended antibiotic for spreading neck infections and acute ulcerative gingivitis. It can be given in combination with a penicillin for severe or unresponsive infections. 1 Fungal infections affect a substantial and increasing proportion of the population. 12 Candidosis is the commonest oral fungal infection. Treatment includes topical polyene (nystatin or amphotericin) or azole (miconazole) antifungal medications. 13 Resistance to polyene antifungals is rare but some species of Candida are less susceptible to azole antifungals and Candida albicans can acquire resistance. 12 These medicines are widely used but there is scant information on dental prescribing trends. Topical antiviral medicines such as acyclovir are used to treat herpes simplex viral infection of the lips. 1 These ointments are available over the counter (OTC) in Australia.
Dental use of antibiotics has previously been examined with a focus on knowledge, indications and preference. [5] [6] [7] 9, 14, 15 Only two studies have investigated longitudinal prescribing trends, in Norway 16 and the Czech Republic. 16, 17 We aimed to describe the dispensed use of antimicrobial medicines prescribed by dental practitioners in concessional beneficiaries in Australia from 2001 to 2012.
METHODS
The medicines considered in this study are those listed only for dental prescribing. All the medicines were available under the Australian Government's subsidized medicine formulary, the Pharmaceutical Benefits Schedule (PBS). The PBS provides a broad range of registered medicines to Australian citizens with two levels of patient co-payments: general ($AU37.70, 2015) and concessional ($AU6. 10, 2015) . 18 Concessional beneficiaries are those who receive social security benefits because they hold a Pensioner card, a Health Care card or a Commonwealth Seniors Health card. Most of the medicines of interest are priced under the general co-payment in any year and these are not recorded by the Department of Human Services that administers the scheme. As data on the dispensed use of medicine for general patients is not available, we analyzed data for concessional patients only. 19 We obtained dispensed medicine use data from publically available sources provided by the Department of Human Sevices. 20 We collected data for each formulation of each medicine between January 2001 and December 2012. The amount of medicine dispensed (as prescriptions) was standardized using the defined daily dose (DDD) per 1000 population per day. The DDD, as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology, is the assumed average maintenance dose per day (expressed in terms of the dose contained in marketed dosage forms) for a medicine used for its main indication in adults. 21 We obtained the concessional population values from the Department of Social Services annual reports and calculated the proportion of concessional beneficiaries using the midyear Australian resident population. 22, 23 There were no values for the population of concessional beneficiaries for the financial year 2011-2012. 22 We estimated the population by extrapolating the average of the proportion of dependants to primary card holders for 2008 to 2010. We were not able to collect information on the dispensed items prescribed by dentists who may also have medical registration and prescribe using their medical prescriber number (e.g. maxillofacial surgeons). These PBS data do not capture those medicines prescribed to inpatients in public hospitals. 19 We suggest that both these sources of dispensed use would be quite small in relation to dispensed use of dental items in the wider community.
We calculated dispensed medicine use for all dentally prescribed antibacterial (amoxicillin, amoxicillin plus clavulanic acid, ampicillin, benzylpenicillin, benzathine benzylpenicillin, cefaclor, cefotaxime, cefuroxime, cephalexin, clindamycin, chloramphenicol, dicloxacillin, doxycycline, erythromycin, flucloxacillin, lincomycin, metronidazole and phenoxymethylpenicillin, procaine penicillin, roxithromycin (listed in 2010), ticarcillin plus clavulanic acid, trimethoprim plus sulfamethoxazole, and vancomycin) and antifungal medicines (amphotericin B and nystatin). We calculated the proportion of dental (vs all other medical excluding emergency doctor supplies) prescribing for the major medicines from each class (summed across all dose formulations) for all beneficiaries for the cumulative 5-year period from 2008 to 2012. The medicines were: amoxicillin, metronidazole, amoxicillin plus clavulanic acid, and amphotericin B. All calculations and graphs were completed using Microsoft Office Excel 2010 (Microsoft, Redmond, WA, USA).
RESULTS
The concessional beneficiary (including dependents) population was 6 693 446 in 2001 and increased to 7 684 132 in 2012. The proportion of concessional beneficiaries to total population ranged 32-36% in any 1 year and the average was 34% over the 12-year period. The antibacterial medicine most frequently prescribed by dental practitioners was amoxicillin and for antifungal medicines this was amphotericin B ( Table 1 ). The proportion of prescribing by dental practitioners (vs all other medical prescribers) was substantial. Almost one in six (15.33%) dispensings for metronidazole were prescribed by dentists as were one in nine dispensings of amoxicillin (11.37%). The proportion of prescribing by dental practitioners was low for amoxicillin plus clavulanic acid (1.07%) and amphotericin B (2.35%).
Antibacterials
Dispensed (standardized) use of antibacterials increased by 50% to 1.032 DDD/1000 concessional beneficiaries per day (number of prescriptions increased by 57%). Amoxicillin accounted for twothirds (66.3%) of all antibacterial prescriptions in 2012, followed by metronidazole (13.6%), amoxicillin plus clavulanic acid (7.1%) and clindamycin (6.1%). These four medicines accounted for nine in 10 (93%) antibiotic prescriptions by dentists in 2012.
Amoxicillin use increased by 49% over 12 years (average annual increase 3.8%; Fig. 1 ). The use of the 500-mg capsule increased from 70% to 90% of all amoxicillin prescriptions over the period whereas the use of the 250-mg capsule decreased from 26% to 6% over the same period. There was negligible use of the other dose formulations. Amoxicillin plus clavulanic acid use increased 197% over 12 years (average annual increase 16.48%; 20% per year for prescriptions; Fig. 1 ). The higher dose formulation (875 mg/ 125 mg) was the most commonly used (78%) in 2012 and use of this product increased threefold to 0.0073 DDD/1,000 concessional beneficiaries per day.
Metronidazole dispensed use increased 49% over the study period to 0.059 DDD/1000 concessional beneficiaries per day in 2012. The use of the two main dose formulations changed over time. In 2001, the 200-mg tablet was the preferred formulation (68% of prescriptions) but in 2012 the 400-mg tablets were more widely used (58% of prescriptions). Use of the other dose formulations was negligible. Clindamycin use increased threefold to 0.0241 DDD/1000 concessional beneficiaries per day in 2012 (317% increase in dispensed use, 380% increase in prescriptions). Use of cephalexin increased 49% over time but use of erythromycin, phenoxymethylpenicillin and doxycycline decreased.
Antifungals
Dispensed use of the two antifungal medicines increased 30% to 0.0073 DDD/1000 concessional beneficiaries per day (2.5% average annual increase). Amphotericin B constituted 74% of antifungal use in 2012 with the remainder being nystatin (Table 1) . Only one formulation of amphotericin B was subsidized and use increased 30% over 12 years. There were two dose formulations for nystatin with the oral liquid dose form accounting for 92% in 2012.
DISCUSSION
This study shows that dispensed use of antibiotics by dental practitioners in Australia has increased over the last decade. Two in three antibacterial dental prescriptions were for amoxicillin. Dispensed use of clindamycin and amoxicillin plus clavulanic acid increased threefold and twofold, respectively. Antifungal use increased substantially and three in four dental prescriptions were for amphotericin B.
In comparison with the Czech Republic, use of antibacterials in dental practice in Australia is somewhat higher. In Australia, use increased from 0.69 to 1.03 DDD/1000 concessional beneficiaries per day between 2001 and 2012. Over the period 2006 to 2012, use in the Czech Republic increased from 0.63 to 0.75 DDD/1000 inhabitants per day. 17 Prescriptions written by general dental practitioners as a proportion of all community antibiotic consumption are significant. In the current study, dental prescribing of metronidazole was 15.3% and for amoxicillin it was 11.4%. Other studies have shown that for antibacterials as a whole, dental prescribing comprises 7% in England (1999), 8 16 and 9% in Wales (2008). 24 Prescribing preferences of dentists in this Australian study have shown that amoxicillin and metronidazole are the most frequently used antibiotics. This is similar to data from England where 78% of all dental prescriptions for antibiotics were for one of these two medicines 8 and Wales where penicillins comprised 67% of all dentally prescribed antibiotics. 24 In Norway, however, prescribing preferences of dentists are very different, with phenoxymethylpenicillin comprising 75% of all dental antibiotic prescriptions. 16 The dental use of this medicine in Norway is 47-fold higher than in Australia. Correspondingly, dental use of amoxicillin in Norway is 19-fold less than in Australia (use is 0.0427 vs 0.8240 DDD/1000 population per day).
The preference of amoxicillin by Australian dentists does not reflect the guidance provided by the ATG 1 for management of acute odontogenic infections. Similarly, the narrow range of cardiac and other conditions recommended for antibiotic prophylaxis prior to dental treatment 1 does not explain the size and proportion of dental prescribing of this medicine. Amoxicillin was also found to be the antibiotic of choice in a previous survey of 61 South Australian dentists. 5 This earlier study also noted a self-reported preference to use lower dose antibiotics. 5 The results of the present study, however, show that dentists are preferentially prescribing higher dose formulations than in the past. This is aligned with ATG guidance that when antibiotics are used, they should be used in appropriately high doses and over the minimum period of time. 1 Additionally, it appears that clindamycin is being substituted for erythromycin where penicillin is not tolerated, and this is in agreement with the guidelines. 1 Both amphotericin B and nystatin are widely used for the treatment of oral candidosis. 25 They can cause gastrointestinal disturbances despite being poorly absorbed in the gut. 25 We showed a modest increase in the dispensed use of antifungal medicines and three in four prescriptions were for amphotericin B. In a self-reported survey of 297 English dentists, nystatin was the preferred antifungal followed by miconazole, amphotericin B and fluconazole (neither azole antifungal is subsidized in Australia). 25 The strength of this study is that it represents the first thorough examination of all subsidized dispensing of medicines prescribed by dentists to Australian concessional beneficiaries. Its longitudinal analysis of dental prescribing provides a useful overview of changes over time as well as insights as to whether the clinical guidelines are being adhered to. Limitations of this study are that data were only available for concessional beneficiaries (who account for approximately one-third of the population) and so these values substantially underestimate the total dental prescribing of these medicines in the wider community. Differences exist in oral health status and dental attendance patterns for the concessional versus the general population 26 and so standardized values for medicine use in the concessional population may not be directly comparable to those for the general population. Future research should determine dental prescribing for both populations. The Department of Health has recently provided data which could be used for this purpose (http://www.pbs.gov.au/info/browse/statistics).
Dispensed prescription data does not allow analysis of actual consumption for the individual prescribed the medicine. Further investigation of patient behaviours is required. These are aggregated data and there was no information on the reason for the prescription, duration of treatment, frequency of repeat administration and co-administration of multiple antibiotics in the same patient. We were not able to collect data for those patients who may be prescribed antimicrobials from a general practitioner for dental issues. There are considerable challenges in determining the use of OTC medicines in managing dental conditions. Additional studies are needed to ascertain the clinical reasoning which leads a dentist to prescribe a particular medicine and to determine the extent to which the clinical guidelines are adhered to.
Practitioners do appear to have responded to some of the recommendations in the clinical guidelines, but not all. The authors suggest that regular continuing education for dental practitioners in the safe and appropriate use of medicines should be mandatory. Other mechanisms to inform, regulate and monitor dental prescribing practices should also be considered. Medication safety is one of the six National Safety and Quality Health Services Standards 27 which must be addressed in order to obtain accreditation of a dental practice. While at this stage accreditation of private dental practices is not mandatory, it would assist in enhancing safety and quality in use of medicines by dental practitioners. Regular surveillance of dental prescribing would also provide feedback to the profession on compliance with the guidelines.
CONCLUSIONS
Dental practitioners are significant prescribers of antibiotics in Australia. There has been an increase in the use of antibiotic and antifungal medicines over the last 12 years. In addition to the risk of ineffective treatment and adverse reactions for the individual, inappropriate prescribing of antibiotics, including by dentists, can accelerate the development of resistant bacterial strains, a problem of potentially global proportions.
